R281
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 104
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.360
- COAGULATION+0.360
- MYOGENESIS+0.360
- ALLOGRAFT_REJECTION+0.300
- APICAL_JUNCTION+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- IL6_JAK_STAT3_SIGNALING+0.290
- NOTCH_SIGNALING+0.280
- TNFA_SIGNALING_VIA_NFKB+0.270
- KRAS_SIGNALING_DN+0.260
Top 10 suppressed
- G2M_CHECKPOINT-0.570
- E2F_TARGETS-0.510
- MYC_TARGETS_V1-0.440
- PROTEIN_SECRETION-0.430
- MITOTIC_SPINDLE-0.370
- UV_RESPONSE_DN-0.370
- ANDROGEN_RESPONSE-0.290
- MTORC1_SIGNALING-0.270
- OXIDATIVE_PHOSPHORYLATION-0.260
- TGF_BETA_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AER7-TTM4-A-1-1-R-A742-41 | — | E | 0.887 |
| 2 | SRR8613743 | — | D | 0.884 |
| 3 | TCGA-BH-A42U-01A-12R-A24H-07 | — | B | 0.881 |
| 4 | SRR2689710 | — | — | 0.881 |
| 5 | 7f51ff28-397d-466f-82b0-25e9c9182ea7 | — | — | 0.881 |
| 6 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.879 |
| 7 | TCGA-GM-A3XN-01A-12R-A22U-07 | — | A | 0.874 |
| 8 | BS_B0SVFK4P | pleomorphic xanthoastrocytoma(PXA) | — | 0.873 |
| 9 | a6b176e9-f4fc-4188-9771-ab2f3e00a4a8 | — | — | 0.871 |
| 10 | fb24d93c-9681-4d45-801f-9dcfd8c5703e | — | — | 0.869 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| COAGULATION | 0.360 | Binimetinib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |